S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:SESN

Sesen Bio Stock Forecast, Price & News

$1.08
-0.01 (-0.92%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.05
$1.14
50-Day Range
$0.73
$1.28
52-Week Range
$0.70
$6.04
Volume
2.89 million shs
Average Volume
12.55 million shs
Market Capitalization
$215.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.64
30 days | 90 days | 365 days | Advanced Chart
Receive SESN News and Ratings via Email

Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter.


Sesen Bio logo

About Sesen Bio

Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. It offers the Vicinium and Proxinium which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Headlines

Sesen Bio, Inc. (NASDAQ:SESN) Sees Large Increase in Short Interest
November 4, 2021 |  americanbankingnews.com
Short Interest in Sesen Bio, Inc. (NASDAQ:SESN) Rises By 23.4%
November 2, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SESN
Employees
27
Year Founded
N/A

Sales & Book Value

Annual Sales
$11.24 million
Book Value
$0.81 per share

Profitability

Net Income
$-22.40 million
Pretax Margin
-492.80%

Debt

Price-To-Earnings

Miscellaneous

Free Float
195,076,000
Market Cap
$215.42 million
Optionable
Optionable

Company Calendar

Last Earnings
11/07/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/21/2022

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

1044th out of 1,391 stocks

Pharmaceutical Preparations Industry

494th out of 669 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Sesen Bio (NASDAQ:SESN) Frequently Asked Questions

Is Sesen Bio a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sesen Bio stock.
View analyst ratings for Sesen Bio
or view top-rated stocks.

How has Sesen Bio's stock been impacted by Coronavirus?

Sesen Bio's stock was trading at $0.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SESN shares have increased by 50.0% and is now trading at $1.08.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Sesen Bio?

Sesen Bio saw a drop in short interest in November. As of November 15th, there was short interest totaling 10,040,000 shares, a drop of 27.7% from the October 31st total of 13,880,000 shares. Based on an average daily volume of 17,200,000 shares, the days-to-cover ratio is currently 0.6 days.
View Sesen Bio's Short Interest
.

When is Sesen Bio's next earnings date?

Sesen Bio is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Sesen Bio
.

How were Sesen Bio's earnings last quarter?

Sesen Bio, Inc. (NASDAQ:SESN) posted its quarterly earnings data on Sunday, November, 7th. The company reported $0.36 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.43.
View Sesen Bio's earnings history
.

What price target have analysts set for SESN?

2 equities research analysts have issued twelve-month price targets for Sesen Bio's stock. Their forecasts range from $3.00 to $8.00. On average, they anticipate Sesen Bio's share price to reach $5.50 in the next year. This suggests a possible upside of 409.3% from the stock's current price.
View analysts' price targets for Sesen Bio
or view top-rated stocks among Wall Street analysts.

Who are Sesen Bio's key executives?

Sesen Bio's management team includes the following people:
  • Thomas R. Cannell, President, Chief Executive Officer & Director
  • Monica Forbes, Chief Financial Officer & Treasurer
  • Jeannick Cizeau, Head of Research
  • Glen C. MacDonald, Chief Technology Officer
  • Dewey McLin, Vice President-Medical Affairs

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK).

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

Who are Sesen Bio's major shareholders?

Sesen Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.58%), Two Sigma Investments LP (1.39%), Geode Capital Management LLC (1.34%), Two Sigma Advisers LP (1.14%), Renaissance Technologies LLC (0.79%) and Deutsche Bank AG (0.45%).

Which institutional investors are selling Sesen Bio stock?

SESN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Deutsche Bank AG, Geode Capital Management LLC, California State Teachers Retirement System, and New York State Common Retirement Fund.

Which institutional investors are buying Sesen Bio stock?

SESN stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Morgan Stanley, Renaissance Technologies LLC, BlackRock Inc., Goldman Sachs Group Inc., Two Sigma Securities LLC, Squarepoint Ops LLC, and State Board of Administration of Florida Retirement System.

How do I buy shares of Sesen Bio?

Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sesen Bio's stock price today?

One share of SESN stock can currently be purchased for approximately $1.08.

How much money does Sesen Bio make?

Sesen Bio has a market capitalization of $215.42 million and generates $11.24 million in revenue each year. The company earns $-22.40 million in net income (profit) each year or ($0.25) on an earnings per share basis.

How many employees does Sesen Bio have?

Sesen Bio employs 27 workers across the globe.

What is Sesen Bio's official website?

The official website for Sesen Bio is www.sesenbio.com.

Where are Sesen Bio's headquarters?

Sesen Bio is headquartered at 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at (617) 444-8550, via email at [email protected], or via fax at 617-858-0911.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.